Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 18:105:adv43052.
doi: 10.2340/actadv.v105.43052.

Evaluating Melanoma Risk in Adult Mastocytosis: Potential Impact of Detection Bias - A Registry-based Study (Sweden)

Anna Bergström  1 , Hans Hägglund  2 , Anders Berglund  3 , Gunnar Nilsson  4 , Mats Lambe  5
Affiliations

Evaluating Melanoma Risk in Adult Mastocytosis: Potential Impact of Detection Bias - A Registry-based Study (Sweden)

Anna Bergström et al. Acta Derm Venereol. .

Abstract

There is some evidence that mastocytosis patients are at increased risk of skin cancer. This study aimed to assess the risk of malignant melanoma (MM), melanoma in situ (Mis), and basal cell carcinoma (BCC). A dataset was generated by individual-level record linkages between Swedish population registers including the National Patient Register (NPR), the Swedish Cancer Register (SCR), and the Population Register (PR). Adult patients with a mastocytosis diagnosis between 2001 and 2018 were identified in the SCR and NPR. For each case, 5 mastocytosis-free comparators matched on age, sex, and county of residence were randomly chosen from the PR. Records of skin cancer were identified in the SCR and NPR. In total, the study encompassed 2,040 mastocytosis patients of whom 63 had a record of MM/Mis and 168 a record of BCC. Compared with comparators, the risk of MM/Mis was more than twofold higher (OR 2.39, 95% CI 1.8-3.2). Risk estimates for BCC were also elevated (OR 1.77, 95% CI 1.49-2.14). When assessing the timing of skin cancers, a substantial portion were diagnosed near index date. Taken together, in the present study these findings of increased risk of MM/Mis and BCC in mastocytosis patients may reflect an influence of detection bias.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Cumulative incidence of MM/Mis and BCC and the timing of the skin cancer diagnosis in relation to mastocytosis diagnosis.
See this image and copyright information in PMC

References

    1. Dahlin JS, Maurer M, Metcalfe DD, Pejler G, Sagi-Eisenberg R, Nilsson G. The ingenious mast cell: contemporary insights into mast cell behavior and function. Allergy 2022; 77: 83–99. 10.1111/all.14881 - DOI - PubMed
    1. Maurer M, Köberle M, Metz M, Biedermann T. Mast cells: promoters of health and modulators of disease. J Allergy Clin Immunol 2019; 144: S1–3. 10.1016/j.jaci.2019.01.048 - DOI - PubMed
    1. Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere 2021; 5: e646. 10.1097/HS9.0000000000000646 - DOI - PMC - PubMed
    1. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016; 137: 35–45. 10.1016/j.jaci.2015.08.034 - DOI - PubMed
    1. Aberer E, Sperr WR, Bretterklieber A, Avian A, Hadzijusufovic E, Kluin-Nelemans HC, et al. Clinical impact of skin lesions in mastocytosis: a multicenter study of the European Competence Network on Mastocytosis. J Invest Dermatol 2021; 141: 1719–1727. 10.1016/j.jid.2020.12.030 - DOI - PubMed

LinkOut - more resources